Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season

Euro Surveill. 2024 Jan;29(2):2300709. doi: 10.2807/1560-7917.ES.2024.29.2.2300709.

Abstract

Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58-64) against influenza A(H1N1), 49% (95% CI: 28-63) against influenza A(H3N2) and 75% (95% CI: 58-85) against influenza B.

Keywords: Epidemiology; Influenza; Influenza Vaccines; Vaccine Effectiveness.

MeSH terms

  • Alberta / epidemiology
  • Canada
  • Case-Control Studies
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza A Virus, H3N2 Subtype
  • Influenza B virus
  • Influenza Vaccines*
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Routinely Collected Health Data
  • Seasons
  • Vaccination
  • Vaccine Efficacy

Substances

  • Influenza Vaccines